Verastem (VSTM) investor relations material

Pipeline and strategy overview

• Two main platforms: a commercial-stage combination therapy for KRAS-mutated low-grade serous ovarian cancer and the VS-7375 KRAS G12D program, both progressing well.

• Commercial product has seen strong uptake, with ongoing efforts to expand prescriber depth in both academic and community settings.

• Phase II programs for VS-7375 are open in pancreas, lung, and colorectal cancers, with phase III trials planned to start by the first half of 2027.

• Emphasis on early patient identification and therapy initiation to replicate strong clinical trial outcomes.

• Confirmatory phase III (RAMP 301) is fully enrolled, with data readout expected next year, aiming to expand into KRAS wild-type populations.

Clinical data and development updates

• RAMP 201 phase II showed an average therapy duration of 18 months for KRAS-mutated LGSOC patients.

• RAMP 205 in frontline metastatic pancreatic cancer showed a 52% response rate and about one year overall survival.

• Upcoming data presentations at IGCS will compare RAMP 201 results to external controls and provide further insights.

• Investigators are exploring the use of combination therapy after progression on RAS inhibitors, especially in pancreatic cancer.

• Multiple phase IIIs are planned for the first half of next year, all in frontline settings.

Differentiation and innovation in RAS/MAPK therapies

• VS-7375 is a dual on/off KRAS G12D inhibitor with high potency, long residence time, and strong selectivity, minimizing off-target effects.

• Dose-dependent exposure allows for higher, well-tolerated dosing, providing flexibility for combinations and drug-drug interactions.

• Mechanistic rationale and preclinical data support combining VS-7375 with EGFR inhibitors in both pancreatic and colorectal cancers.

• Clinical strategy includes showing robust data in each tumor type, with pancreatic cancer as a proving ground and colorectal as a significant unmet need.

• Lung cancer studies include a cohort focused on brain metastases, aiming to establish best-in-class status.